Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    Alizapride

    go.drugbank.com/drugs/DB01425
    Investigational

    This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively. … Alizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects.

  2. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A Inhibitors
  3. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. … It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  4. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics. … Blonanserin is an atypical antipsychotic approved in Japan in January, 2008.

  5. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain). … NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  6. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. … HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine.

  7. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  8. Drug

    Barnidipine

    go.drugbank.com/drugs/DB09227
    Investigational

    after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842]. … Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall [L1131] and selectivity against cardiovascular L-type

  9. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  10. Drug

    Magnesium salicylate

    go.drugbank.com/drugs/DB01397
    Approved

    Magnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations. … six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a